Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

5P - Tumor microenvironment cellular crosstalk predicts response to adoptive TIL therapy in melanoma patients

Date

08 Dec 2022

Session

Poster Display

Presenters

Denarda Dangaj

Citation

Annals of Oncology (2022) 16 (suppl_1): 100100-100100. 10.1016/iotech/iotech100100

Authors

E. Ghisoni1, D. Dangaj2, J. Chiffelle2, A. Orcurto3, J. Dagher4, N. Fahr1, U. Dafni5, C. Sempoux4, O.A. Michielin6, L. Trueb1, A. Harari2, G. Coukos7

Author affiliations

  • 1 CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne/CH
  • 2 Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne/CH
  • 3 Lausanne University Hospital, Lausanne/CH
  • 4 CHUV - Lausanne University Hospital, Lausanne/CH
  • 5 Frontier Science Foundation – Hellas and National and Kapodistrian University of Athens, Athens/GR
  • 6 Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne/CH
  • 7 UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Lausanne/CH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5P

Background

Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) has proven efficacious in metastatic melanoma (Mel). Nevertheless, long-term clinical efficacy remains unsatisfactory for the majority of patients. Therefore, understanding TILs and the orchestrated tumor-microenvironment (TME) states associated with clinical response is of paramount importance.

Methods

We report the translational analysis of a single-center phase I study to assess feasibility and efficacy of TIL-ACT in Mel patients (NCT03475134). We performed comprehensive translational studies on patients` tumor longitudinal samples including multispectral immuno-fluorescence (mIF) imaging, bulk RNA-sequencing and single-cell RNA-sequencing before and after TILs infusion (30 days).

Results

Thirteen patients successfully completed TIL-ACT therapy and were included in the analysis. Best overall response was 46.1% (6/13) at 3 months, including two patients with ongoing complete response 3 years after infusion. Responders (Rs) exhibited immunogenic tumor cell states with higher inferred CNVs and overexpressed DNA sensing/IFN and class I antigen presentation-related genes. Multiplex IF imaging revealed that Rs had increased densities of polyfunctional intra-epithelial (ie)CD8+ T cells marked by higher PD-1 expression at baseline, and these cells persisted 30 days after TILs infusion. Single-cell transcriptomic analyses confirmed higher cytotoxic and exhaustion CD8 T cell states at baseline. PDCD1 (PD-1), CXCL13, TNFRSF9 (CD137), GZMB, HAVCR2 (TIM3) and PRF1 genes were overexpressed in CD8+ TILs and associated to clinical responses. Cell-cell interaction predictions corroborated by spatial neighborhood analyses revealed that tumors of Rs were highly enriched for ie-and stromal T-cell networks involving activated myeloid and costimulatory B cells. Successful TIL-ACT therapy reprogrammed the myeloid compartment and further increased CD8 TIL-myeloid cell networks.

Conclusions

Our systematic target discovery study reveals CD8 T-cell network-based biomarkers that could improve patient selection and guide the design of ACT clinical trials.

Clinical trial identification

NCT03475134.

Legal entity responsible for the study

Centre Hospitalier Universitaire Vaudois (CHUV), Ludwig Institute for Cancer Research.

Funding

Centre Hospitalier Universitaire Vaudois, Lausanne Branch of the Ludwig Insitute for Cancer Research.

Disclosure

O.A. Michielin: Financial Interests, Institutional, Invited Speaker: BMS, Amgen, Pierre Fabre, Roche, BMS; Financial Interests, Institutional, Advisory Board: BMS, Amgen, Roche, Novartis, Pierre Fabre, MSD; Financial Interests, Personal, Other, Advisory Role: BMS, MSD, Roche, Novartis, Pierre Fabre, Amgen, GSL; Financial Interests, Institutional, Research Grant: BMS, MSD, Pierre Fabre, Amgen, Merck; Financial Interests, Institutional, Funding: BMS, MSD, Pierre Fabre, Amgen, MSD; Non-Financial Interests, Personal, Principal Investigator: BMS, MSD, Amgen, Roche, Pierre Fabre, Novartis. G. Coukos: Financial Interests, Personal, Invited Speaker: CHUV. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.